MedTrace Logo

F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis

NCT02414230 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2020-09-22

No results posted yet for this study

Summary

The purpose of this research study is to evaluate tau distribution in the brain of subjects with: ALS caused by different genetic mutations, any mutation carriers (with or without symptoms), any non-mutation carrier, any sporadic FTD, normal controls.

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG

Drug: F 18 T807

Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.

Sponsors & Collaborators

  • Tammie L. S. Benzinger, MD, PhD

    lead OTHER

Principal Investigators

  • Tammie Benzinger, MD, PhD · Washington University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-09-19
Completion
2020-06-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02414230 on ClinicalTrials.gov